| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 1,028 | 1,033* | 1,397 | 1,390 |
| Research and development | 2,865 | 2,856* | 2,436 | 1,246 |
| General and administrative | 5,282 | 4,445* | 3,443 | 1,682 |
| Total operating expenses | 8,147 | 7,301* | 5,879 | 2,928 |
| Operating loss | -7,119 | -6,268* | -4,482 | -1,538 |
| Financing expenses | NaN | NaN | NaN | -150 |
| Financing expense | NaN | 765* | NaN | NaN |
| Change in fair value of derivative instruments | NaN | 16,054* | NaN | -6,512 |
| Warrant issuance costs | NaN | 241* | NaN | NaN |
| Interest income | 190 | -13* | 59 | 27 |
| Interest expense | 17 | 137* | NaN | NaN |
| Total other income (expense) | 173 | -17,210* | 59 | 6,689 |
| Net loss | -6,946 | -23,478 | -4,423 | 5,151 |
| Basic EPS | -1.05 | -0.302 | -0.04 | 0.02 |
| Diluted EPS | -1.05 | -0.302 | -0.04 | -0.01 |
| Basic Average Shares | 6,646,049 | 77,804,612* | 107,428,969 | 48,388,862 |
| Diluted Average Shares | 6,646,049 | 77,804,612* | 107,428,969 | 209,154,994 |
PLUS THERAPEUTICS, INC. (PSTV)
PLUS THERAPEUTICS, INC. (PSTV)